Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Introduction: Cervical cancer is the leading cause of cancer-related death in women, so novel therapeutic approaches are needed to improve the effectiveness of current therapies or extend their activity. In recent decades, graphene analogs, such as Mxene, an emerging class of two-dimensional (2D) graphene analogs, have been drawing considerable attention based on their intrinsic physicochemical properties and performance as potential candidates for tumor therapy, particularly for therapeutic purposes. Here we explored the targeted drug delivery in cervical cancer in in vivo model. Mxene-based nanocarriers are not able to be precisely controlled in cancer treatment. Method: To solve this problem, the titanium carbide-magnetic core-shell nanocarrier (Ti₃C₂-Fe₃O₄@SiO₂-FA) is also developed to provide synergetic anticancer with magnetic controlling ability along with pH-responsive drug release. A xenograft model of the cervix was used to investigate the effects of Cisplatin alone, or in combination with Ti₃C₂@FA and Ti₃C₂@ Fe₃O₄@SiO₂-FA, on tumor growth following histological staining for evaluation of necrosis. Result and Discussion: A significant tumor-growth suppression effect is shown when the Ti₃C₂-Fe₃O₄@SiO₂-FA nanocarrier is magnetically controlled Cisplatin drug release. It reveals a synergistic therapeutic efficacy used in conjunction with pharmaceuticals (p < .001). According to the in vivo study, the Ti₃C₂@FA@Cisplatin nanocomposite exhibits less tumor growth than the drug alone or Ti₃C₂@FA@Cisplatin via increasing necrosis effect (p < .001). Through this study, Mxene nanosheets are expanded for biomedical applications, not only through the fabrication of biocompatible magnetic Mxene nanocomposite but also through the development of functionalization strategies that enable the magnetic Ti₃C₂ nanocomposite to load high levels of Cisplatin for cervical cancer treatment (242.5%). Hence, Ti₃C₂-Fe₃O₄@SiO₂-FA nanocarriers would be promising candidates to improve cancer treatment efficiency.